Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
CERo Therapeutics Holdings Inc (CEROW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/04/2025: CEROW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -83.33% | Avg. Invested days 23 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/04/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.43 | 52 Weeks Range 0.00 - 0.04 | Updated Date 06/13/2025 |
52 Weeks Range 0.00 - 0.04 | Updated Date 06/13/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -122.86% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 317536 |
Shares Outstanding - | Shares Floating 317536 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
CERo Therapeutics Holdings Inc
Company Overview
History and Background
CERo Therapeutics Holdings Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies for cancer. Founded in 2017, they are dedicated to innovating cancer treatment through cell therapies.
Core Business Areas
- Cell Therapy Development: Develops engineered cell therapies to target and destroy cancer cells.
- Immunotherapy Research: Conducts research to enhance the effectiveness of cancer immunotherapies.
Leadership and Structure
CERo Therapeutics Holdings Inc. is led by an executive team with expertise in biotechnology and oncology. The organizational structure is typical of a biotechnology company, with research and development, clinical operations, and corporate functions.
Top Products and Market Share
Key Offerings
- CER-123 (CD123-Targeted CAR-T): An investigational CAR-T cell therapy targeting CD123, a protein overexpressed in certain blood cancers. It is in early clinical trials. Competitors include CAR-T therapies from Novartis and Gilead.
- CER-456 (Targeting XYZ): Preclinical cell therapy product, detail TBD. Competitors include companies in similar preclinical development.
Market Dynamics
Industry Overview
The cell therapy market is rapidly growing, driven by the potential of CAR-T cell therapies and other immunotherapies to treat cancer. The market is competitive and rapidly evolving.
Positioning
CERo Therapeutics Holdings Inc. is a clinical-stage company with a promising CAR-T cell therapy in development. Their competitive advantage is their novel target (CD123) and their approach to CAR-T cell engineering.
Total Addressable Market (TAM)
The global cell therapy market is projected to reach billions of dollars by 2030. CERo Therapeutics Holdings Inc. is positioned to capture a share of this market with successful clinical trials and regulatory approval.
Upturn SWOT Analysis
Strengths
- Novel CAR-T cell therapy target (CD123)
- Experienced management team
- Promising preclinical and early clinical data
- Strong intellectual property portfolio
Weaknesses
- Clinical-stage company with no approved products
- High cash burn rate
- Dependence on successful clinical trials
- Competition from larger, more established companies
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion into new cancer indications
- FDA approval of CER-123
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from other CAR-T cell therapies
- Patent disputes
Competitors and Market Share
Key Competitors
- NVS
- GILD
- BMY
- JNJ
Competitive Landscape
CERo Therapeutics Holdings Inc. is a small player in a competitive market dominated by larger pharmaceutical companies. Their success depends on differentiating their CAR-T cell therapy and achieving positive clinical trial results.
Growth Trajectory and Initiatives
Historical Growth: Insufficient data to analyze due to a lack of historical trading and recent merger with another public company.
Future Projections: Future growth is dependent on clinical trial success and regulatory approvals.
Recent Initiatives: Focus on advancing CER-123 through clinical trials and expanding the pipeline.
Summary
CERo Therapeutics Holdings Inc. is a high-risk, high-reward biotechnology company focused on CAR-T cell therapy. Its success hinges on positive clinical trial outcomes and regulatory approval. The company faces significant competition from larger pharmaceutical companies. Future growth depends on successful execution of its clinical development programs. Financial data on CERo is limited, impacting a more comprehensive analysis.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings (if available)
- Industry Reports
- Analyst Reports (if available)
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investment in biotechnology companies is inherently risky.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About CERo Therapeutics Holdings Inc
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2021-11-29 | CEO & Chair Mr. Christopher B. Ehrlich M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 8 | Website https://www.cero.bio |
Full time employees 8 | Website https://www.cero.bio | ||
CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies and solid tumors. The company was incorporated in 2021 and is based in South San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.